In this issue of Blood, Kramer et al have provided a long-term update on the outcomes of patients enrolled in the German CLL Study Group CLL3X trial who underwent a matched related or unrelated allogeneic hematopoietic cell transplantation (allo-HCT) with a reduced-intensity fludarabine/alkylator-based approach for high-risk chronic lymphocytic leukemia (HR-CLL).1

中文翻译：

---

CLL 同种异体移植的结果是否仍然相关？

在本期《血液》中，Kramer 等人提供了德国 CLL 研究组 CLL3X 试验中患者接受匹配相关或不相关同种异体造血细胞移植 (allo-HCT) 的结果的长期更新高危慢性淋巴细胞白血病 (HR-CLL) 的基于氟达拉滨/烷化剂的强度方法1。